Thomas J Scriba

List of Publications by Year
in descending order

227	15,465	19657 61	22832 112
papers	citations	h-index	g-index

254	254	254	14254
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Diagnostic Accuracy of the Cepheid 3-gene Host Response Fingerstick Blood Test in a Prospective, Multi-site Study: Interim Results. Clinical Infectious Diseases, 2022, 74, 2136-2141.	5.8	46
2	Molecular Detection of Airborne Mycobacterium tuberculosis in South African High Schools. American Journal of Respiratory and Critical Care Medicine, 2022, 205, 350-356.	5.6	10
3	CD4 and CD8 co-receptors modulate functional avidity of CD1b-restricted T cells. Nature Communications, 2022, 13, 78.	12.8	8
4	Effects of BCG vaccination on donor unrestricted T cells in two prospective cohort studies. EBioMedicine, 2022, 76, 103839.	6.1	19
5	REL and BHLHE40 Variants Are Associated with IL-12 and IL-10 Responses and Tuberculosis Risk. Journal of Immunology, 2022, 208, 1352-1361.	0.8	6
6	The effect of host factors on discriminatory performance of a transcriptomic signature of tuberculosis risk. EBioMedicine, 2022, 77, 103886.	6.1	2
7	Durable Expansion of TCR-Î´ Meta-Clonotypes After BCG Revaccination in Humans. Frontiers in Immunology, 2022, 13, 834757.	4.8	4
8	Targeted Gene Expression Profiling of Human Myeloid Cells From Blood and Lung Compartments of Patients With Tuberculosis and Other Lung Diseases. Frontiers in Immunology, 2022, 13, 839747.	4.8	4
9	Prospective multicentre head-to-head validation of host blood transcriptomic biomarkers for pulmonary tuberculosis by real-time PCR. Communications Medicine, 2022, 2, .	4.2	15
10	Clinical predictors of pulmonary tuberculosis among South African adults with HIV. EClinicalMedicine, 2022, 45, 101328.	7.1	7
11	Host transcriptomic signatures of tuberculosis can predict immune reconstitution inflammatory syndrome in HIV patients. European Journal of Immunology, 2022, , .	2.9	3
12	Evaluation of a transcriptomic signature of tuberculosis risk in combination with an interferon gamma release assay: A diagnostic test accuracy study. EClinicalMedicine, 2022, 47, 101396.	7.1	3
13	Mycobacterium tuberculosis infection, immune activation, and risk of HIV acquisition. PLoS ONE, 2022, 17, e0267729.	2.5	2
14	Non-volatile organic compounds in exhaled breath particles correspond to active tuberculosis. Scientific Reports, 2022, 12, 7919.	3.3	3
15	T cell responses to Mycobacterium indicus pranii immunotherapy and adjunctive glucocorticoid therapy in tuberculous pericarditis. Vaccine: X, 2022, 11, 100177.	2.1	2
16	Transcriptomics for child and adolescent tuberculosis*. Immunological Reviews, 2022, 309, 97-122.	6.0	17
17	Immune Profiling Enables Stratification of Patients With Active Tuberculosis Disease or Mycobacteriu m tuberculosis Infection. Clinical Infectious Diseases, 2021, 73, e3398-e3408.	5.8	18
18	Immune profiling of Mycobacterium tuberculosis-specific T cells in recent and remote infection. EBioMedicine, 2021, 64, 103233.	6.1	17

#	Article	IF	Citations
19	Inflammatory Determinants of Differential Tuberculosis Risk in Pre-Adolescent Children and Young Adults. Frontiers in Immunology, 2021, 12, 639965.	4.8	7
20	T Cells Specific for a Mycobacterial Glycolipid Expand after Intravenous Bacillus Calmetteâ€“GuÃ©rin Vaccination. Journal of Immunology, 2021, 206, 1240-1250.	0.8	18
21	Biomarker-guided tuberculosis preventive therapy (CORTIS): a randomised controlled trial. Lancet Infectious Diseases, The, 2021, 21, 354-365.	9.1	84
22	Safety and immunogenicity of the adjunct therapeutic vaccine ID93â€ˆ+â€ˆGLA-SE in adults who have completed treatment for tuberculosis: a randomised, double-blind, placebo-controlled, phase 2a trial. Lancet Respiratory Medicine,the, 2021, 9, 373-386.	10.7	46
23	Effect of Inflammatory Cytokines/Chemokines on Pulmonary Tuberculosis Culture Conversion and Disease Severity in HIV-Infected and -Uninfected Individuals From South Africa. Frontiers in Immunology, 2021, 12, 641065.	4.8	11
24	Validation of a host blood transcriptomic biomarker for pulmonary tuberculosis in people living with HIV: a prospective diagnostic and prognostic accuracy study. The Lancet Global Health, 2021, 9, e841-e853.	6.3	34
25	HLA-DR Marks Recently Divided Antigen-Specific Effector CD4 T Cells in Active Tuberculosis Patients. Journal of Immunology, 2021, 207, 523-533.	0.8	33
26	Antigen-Specific T-Cell Activation Distinguishes between Recent and Remote Tuberculosis Infection. American Journal of Respiratory and Critical Care Medicine, 2021, 203, 1556-1565.	5.6	25
27	Multidimensional analysis of immune responses identified biomarkers of recent Mycobacterium tuberculosis infection. PLoS Computational Biology, 2021, 17, e1009197.	3.2	1
28	Host blood transcriptomic biomarkers of tuberculosis disease in people living with HIV: a systematic review protocol. BMJ Open, 2021, 11, e048623.	1.9	5
29	Mycobacterium tuberculosis-Specific T Cell Functional, Memory, and Activation Profiles in QuantiFERON-Reverters Are Consistent With Controlled Infection. Frontiers in Immunology, 2021, 12, 712480.	4.8	8
30	Longitudinal Dynamics of a Blood Transcriptomic Signature of Tuberculosis. American Journal of Respiratory and Critical Care Medicine, 2021, 204, 1463-1472.	5.6	15
31	The impact of blood transcriptomic biomarker targeted tuberculosis preventive therapy in people living with HIV: a mathematical modelling study. BMC Medicine, 2021, 19, 252.	5.5	4
32	A simple assay to quantify mycobacterial lipid antigen-specific T cell receptors in human tissues and blood. PLoS Neglected Tropical Diseases, 2021, 15, e0010018.	3.0	0
33	The effect of new Mycobacterium tuberculosis infection on the sensitivity of prognostic TB signatures. International Journal of Tuberculosis and Lung Disease, 2021, 25, 1001-1005.	1.2	1
34	Postnatal Expansion, Maturation, and Functionality of MR1T Cells in Humans. Frontiers in Immunology, 2020, 11, 556695.	4.8	14
35	Multidimensional analyses reveal modulation of adaptive and innate immune subsets by tuberculosis vaccines. Communications Biology, 2020, 3, 563.	4.4	14
36	Fetal public VÎ³9VÎ´2 T cells expand and gain potent cytotoxic functions early after birth. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 18638-18648.	7.1	43

#	Article	IF	Citations
37	BCG Vaccination of Infants Confers Mycobacterium tuberculosis Strain-Specific Immune Responses by Leukocytes. ACS Infectious Diseases, 2020, 6, 3141-3146.	3.8	5
38	Key recent advances in TB vaccine development and understanding of protective immune responses against Mycobacterium tuberculosis. Seminars in Immunology, 2020, 50, 101431.	5.6	57
39	Diagnostic accuracy of plasma kynurenine/tryptophan ratio, measured by enzyme-linked immunosorbent assay, for pulmonary tuberculosis. International Journal of Infectious Diseases, 2020, 99, 441-448.	3.3	12
40	Performance of diagnostic and predictive host blood transcriptomic signatures for Tuberculosis disease: A systematic review and meta-analysis. PLoS ONE, 2020, 15, e0237574.	2.5	39
41	Blood transcriptional signatures for tuberculosis testing. Lancet Respiratory Medicine,the, 2020, 8, 330-331.	10.7	6
42	Immune Phenotype and Functionality of Mtb-Specific T-Cells in HIV/TB Co-Infected Patients on Antiretroviral Treatment. Pathogens, 2020, 9, 180.	2.8	6
43	Renewing the Fight Against TB with an Old Vaccine. Cell, 2020, 180, 829-831.	28.9	6
44	Regional changes in tuberculosis disease burden among adolescents inÂSouth AfricaÂ(2005â€“2015). PLoS ONE, 2020, 15, e0235206.	2.5	5
45	Headway made towards biosignatures for incipient tuberculosis. Lancet Respiratory Medicine,the, 2020, 8, 328-330.	10.7	5
46	Immune correlates of tuberculosis disease and risk translate across species. Science Translational Medicine, 2020, 12, .	12.4	52
47	Peripheral Blood Mucosal-Associated Invariant T Cells in Tuberculosis Patients and Healthy Mycobacterium tuberculosis-Exposed Controls. Journal of Infectious Diseases, 2020, 222, 995-1007.	4.0	19
48	Analyzing the Mycobacterium tuberculosis immune response by T-cell receptor clustering with GLIPH2 and genome-wide antigen screening. Nature Biotechnology, 2020, 38, 1194-1202.	17.5	282
49	RISK6, a 6-gene transcriptomic signature of TB disease risk, diagnosis and treatment response. Scientific Reports, 2020, 10, 8629.	3.3	90
50	S100A8/A9 regulates CD11b expression and neutrophil recruitment during chronic tuberculosis. Journal of Clinical Investigation, 2020, 130, 3098-3112.	8.2	85
51	Dose Optimization of H56:IC31 Vaccine for Tuberculosis-Endemic Populations. A Double-Blind, Placebo-controlled, Dose-Selection Trial. American Journal of Respiratory and Critical Care Medicine, 2019, 199, 220-231.	5.6	75
52	Potential population level impact on tuberculosis incidence of using an mRNA expression signature correlate-of-risk test to target tuberculosis preventive therapy. Scientific Reports, 2019, 9, 11126.	3.3	13
53	Multinomial modelling of TB/HIV co-infection yields a robust predictive signature and generates hypotheses about the HIV+TB+ disease state. PLoS ONE, 2019, 14, e0219322.	2.5	11
54	Tuberculosis Vaccine Development: Progress in Clinical Evaluation. Clinical Microbiology Reviews, 2019, 33, .	13.6	70

#	Article	IF	Citations
55	Final Analysis of a Trial of M72/AS01_E Vaccine to Prevent Tuberculosis. New England Journal of Medicine, 2019, 381, 2429-2439.	27.0	350
56	Live-attenuated Mycobacterium tuberculosis vaccine MTBVAC versus BCG in adults and neonates: a randomised controlled, double-blind dose-escalation trial. Lancet Respiratory Medicine,the, 2019, 7, 757-770.	10.7	92
57	Plasma Type I IFN Protein Concentrations in Human Tuberculosis. Frontiers in Cellular and Infection Microbiology, 2019, 9, 296.	3.9	10
58	Diagnostic Accuracy of Early Secretory Antigenic Target-6â€“Free Interferon-gamma Release Assay Compared to QuantiFERON-TB Gold In-tube. Clinical Infectious Diseases, 2019, 69, 1724-1730.	5.8	12
59	Protection against tuberculosis by mucosal BCG administration. Nature Medicine, 2019, 25, 199-201.	30.7	3
60	Detection of Tuberculosis Recurrence, Diagnosis and Treatment Response by a Blood Transcriptomic Risk Signature in HIV-Infected Persons on Antiretroviral Therapy. Frontiers in Microbiology, 2019, 10, 1441.	3.5	46
61	Temporal trends in the prevalence of Mycobacterium tuberculosis infection in South African adolescents. International Journal of Tuberculosis and Lung Disease, 2019, 23, 571-578.	1.2	9
62	Performance of host blood transcriptomic signatures for diagnosing and predicting progression to tuberculosis disease in HIV-negative adults and adolescents: a systematic review protocol. BMJ Open, 2019, 9, e026612.	1.9	7
63	Moving tuberculosis vaccines from theory to practice. Nature Reviews Immunology, 2019, 19, 550-562.	22.7	101
64	Select sequencing of clonally expanded CD8⁺T cells reveals limits to clonal expansion. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 8995-9001.	7.1	68
65	Discovery and validation of a prognostic proteomic signature for tuberculosis progression: A prospective cohort study. PLoS Medicine, 2019, 16, e1002781.	8.4	72
66	Immunometabolic Signatures Predict Risk of Progression to Active Tuberculosis and Disease Outcome. Frontiers in Immunology, 2019, 10, 527.	4.8	40
67	A comparison of antigen-specific T cell responses induced by six novel tuberculosis vaccine candidates. PLoS Pathogens, 2019, 15, e1007643.	4.7	79
68	MR1-Independent Activation of Human Mucosal-Associated Invariant T Cells by Mycobacteria. Journal of Immunology, 2019, 203, 2917-2927.	0.8	55
69	Batf2 differentially regulates tissue immunopathology in Type 1 and Type 2 diseases. Mucosal Immunology, 2019, 12, 390-402.	6.0	19
70	Cytomegalovirus infection is a risk factor for tuberculosis disease in infants. JCI Insight, 2019, 4, .	5.0	42
71	Four-Gene Pan-African Blood Signature Predicts Progression to Tuberculosis. American Journal of Respiratory and Critical Care Medicine, 2018, 197, 1198-1208.	5.6	217
72	CD1b Tetramers Identify T Cells that Recognize Natural and Synthetic Diacylated Sulfoglycolipids from Mycobacterium tuberculosis. Cell Chemical Biology, 2018, 25, 392-402.e14.	5.2	23

#	Article	IF	Citations
73	Comparison of CyTOF assays across sites: Results of a six-center pilot study. Journal of Immunological Methods, 2018, 453, 37-43.	1.4	50
74	Validation of a CD1b tetramer assay for studies of human mycobacterial infection or vaccination. Journal of Immunological Methods, 2018, 458, 44-52.	1.4	22
75	Safety and immunogenicity of the novel tuberculosis vaccine ID93â€˜+â€˜GLA-SE in BCG-vaccinated healthy adults in South Africa: a randomised, double-blind, placebo-controlled phase 1 trial. Lancet Respiratory Medicine,the, 2018, 6, 287-298.	10.7	122
76	Sequence-based HLA-A, B, C, DP, DQ, and DR typing of 159 individuals from the Worcester region of the Western Cape province of South Africa. Human Immunology, 2018, 79, 143-144.	2.4	7
77	T-cell biomarkers for diagnosis of tuberculosis: candidate evaluation by a simple whole blood assay for clinical translation. European Respiratory Journal, 2018, 51, 1800153.	6.7	65
78	Protein kinase C-delta (PKCÎ´), a marker of inflammation and tuberculosis disease progression in humans, is important for optimal macrophage killing effector functions and survival in mice. Mucosal Immunology, 2018, 11, 496-511.	6.0	28
79	Comparison of haematology and biochemistry parameters in healthy South African infants with laboratory reference intervals. Tropical Medicine and International Health, 2018, 23, 63-68.	2.3	6
80	Diagnostic performance of an optimized transcriptomic signature of risk of tuberculosis in cryopreserved peripheral blood mononuclear cells. Tuberculosis, 2018, 108, 124-126.	1.9	49
81	120. A Randomized Double-blind Trial Assessing the Efficacy of M72/AS01E Vaccine Against Pulmonary Tuberculosis Disease in Adults With Latent Mycobacterium tuberculosis Infection. Open Forum Infectious Diseases, 2018, 5, S5-S6.	0.9	0
82	Prospects for a vaccine to prevent HIV-related tuberculosis. Current Opinion in HIV and AIDS, 2018, 13, 522-527.	3.8	5
83	Safety and Immunogenicity of Newborn MVA85A Vaccination and Selective, Delayed Bacille Calmette-Guerin for Infants of Human Immunodeficiency Virus-Infected Mothers: A Phase 2 Randomized, Controlled Trial. Clinical Infectious Diseases, 2018, 66, 554-563.	5.8	32
84	The effect of antiretroviral treatment on selected genes in whole blood from HIV-infected adults sensitised by Mycobacterium tuberculosis. PLoS ONE, 2018, 13, e0209516.	2.5	3
85	Metabolite changes in blood predict the onset of tuberculosis. Nature Communications, 2018, 9, 5208.	12.8	129
86	Toll-like receptor chaperone HSP90B1 and the immune response to Mycobacteria. PLoS ONE, 2018, 13, e0208940.	2.5	12
87	Allelic resolution NGS HLA typing of Class I and Class II loci and haplotypes in Cape Town, South Africa. Human Immunology, 2018, 79, 839-847.	2.4	22
88	Using vaccine Immunostimulation/Immunodynamic modelling methods to inform vaccine dose decision-making. Npj Vaccines, 2018, 3, 36.	6.0	16
89	Phase 2b Controlled Trial of M72/AS01_EVaccine to Prevent Tuberculosis. New England Journal of Medicine, 2018, 379, 1621-1634.	27.0	319
90	Can we predict tuberculosis cure? What tools are available?. European Respiratory Journal, 2018, 52, 1801089.	6.7	73

#	Article	IF	Citations
91	Differential DNA methylation of potassium channel KCa3.1 and immune signalling pathways is associated with infant immune responses following BCG vaccination. Scientific Reports, 2018, 8, 13086.	3.3	33
92	Integrating Non-human Primate, Human, and Mathematical Studies to Determine the Influence of BCG Timing on H56 Vaccine Outcomes. Frontiers in Microbiology, 2018, 9, 1734.	3.5	12
93	Elevated IgG Responses in Infants Are Associated With Reduced Prevalence of Mycobacterium tuberculosis Infection. Frontiers in Immunology, 2018, 9, 1529.	4.8	16
94	Diagnostic Challenge of Tuberculosis Heterogeneity. Seminars in Respiratory and Critical Care Medicine, 2018, 39, 286-296.	2.1	1
95	Functional, Antigen-Specific Stem Cell Memory (TSCM) CD4+ T Cells Are Induced by Human Mycobacterium tuberculosis Infection. Frontiers in Immunology, 2018, 9, 324.	4.8	44
96	A Serum Circulating miRNA Signature for Short-Term Risk of Progression to Active Tuberculosis Among Household Contacts. Frontiers in Immunology, 2018, 9, 661.	4.8	42
97	Prevention of M. tuberculosis Infection with H4:IC31 Vaccine or BCG Revaccination. New England Journal of Medicine, 2018, 379, 138-149.	27.0	532
98	A multi-cohort study of the immune factors associated with M. tuberculosis infection outcomes. Nature, 2018, 560, 644-648.	27.8	184
99	A Diverse Lipid Antigenâ€“Specific TCR Repertoire Is Clonally Expanded during Active Tuberculosis. Journal of Immunology, 2018, 201, 888-896.	0.8	30
100	Considerations for biomarker-targeted intervention strategies for tuberculosis disease prevention. Tuberculosis, 2018, 109, 61-68.	1.9	28
101	Safety and Immunogenicity of Adenovirus 35 Tuberculosis Vaccine Candidate in Adults with Active or Previous Tuberculosis. A Randomized Trial. American Journal of Respiratory and Critical Care Medicine, 2017, 195, 1171-1180.	5.6	26
102	Human Immunology of Tuberculosis. Microbiology Spectrum, 2017, 5, .	3.0	101
103	POLICY-DRIVEN INTERVENTIONS: TUBERCULOSIS. BMJ Global Health, 2017, 2, A4.1-A4.	4.7	0
104	Serial QuantiFERON testing and tuberculosis disease risk among young children: an observational cohort study. Lancet Respiratory Medicine,the, 2017, 5, 282-290.	10.7	110
105	The SIGLEC14 null allele is associated with Mycobacterium tuberculosis- and BCG-induced clinical and immunologic outcomes. Tuberculosis, 2017, 104, 38-45.	1.9	16
106	Prevalence of latent TB infection and TB disease among adolescents in high TB burden countries in Africa: a systematic review protocol. BMJ Open, 2017, 7, e014609.	1.9	3
107	A Functional Toll-Interacting Protein Variant Is Associated with Bacillus Calmette-GuÃ©rinâ€“Specific Immune Responses and Tuberculosis. American Journal of Respiratory and Critical Care Medicine, 2017, 196, 502-511.	5.6	38
108	Antigen Availability Shapes T Cell Differentiation and Function during Tuberculosis. Cell Host and Microbe, 2017, 21, 695-706.e5.	11.0	164

#	Article	IF	Citations
109	Identifying specificity groups in the T cell receptor repertoire. Nature, 2017, 547, 94-98.	27.8	825
110	Long-lasting tuberculous pleurisy. European Respiratory Journal, 2017, 49, 1700356.	6.7	3
111	The CSF Immune Response in HIV-1â€“Associated Cryptococcal Meningitis: Macrophage Activation, Correlates of Disease Severity, and Effect of Antiretroviral Therapy. Journal of Acquired Immune Deficiency Syndromes (1999), 2017, 75, 299-307.	2.1	23
112	Host blood RNA signatures predict the outcome of tuberculosis treatment. Tuberculosis, 2017, 107, 48-58.	1.9	156
113	The Cross-Species Mycobacterial Growth Inhibition Assay (MGIA) Project, 2010â€“2014. Vaccine Journal, 2017, 24, .	3.1	41
114	Optimization and Interpretation of Serial QuantiFERON Testing to Measure Acquisition of Mycobacterium tuberculosis Infection. American Journal of Respiratory and Critical Care Medicine, 2017, 196, 638-648.	5.6	124
115	Differential Recognition ofMycobacterium tuberculosisâ€“Specific Epitopes as a Function of Tuberculosis Disease History. American Journal of Respiratory and Critical Care Medicine, 2017, 196, 772-781.	5.6	39
116	Impact of isoniazid preventive therapy on the evaluation of long-term effectiveness of infant MVA85A vaccination. International Journal of Tuberculosis and Lung Disease, 2017, 21, 778-783.	1.2	6
117	H1:IC31 vaccination is safe and induces long-lived TNF-Î±+IL-2+CD4 T cell responses in M. tuberculosis infected and uninfected adolescents: A randomized trial. Vaccine, 2017, 35, 132-141.	3.8	34
118	Human Immunology of Tuberculosis. , 2017, , 213-237.		6
119	TBVAC2020: Advancing Tuberculosis Vaccines from Discovery to Clinical Development. Frontiers in Immunology, 2017, 8, 1203.	4.8	44
120	Polyfunctional CD4+ T Cells As Targets for Tuberculosis Vaccination. Frontiers in Immunology, 2017, 8, 1262.	4.8	154
121	Application of a whole blood mycobacterial growth inhibition assay to study immunity against Mycobacterium tuberculosis in a high tuberculosis burden population. PLoS ONE, 2017, 12, e0184563.	2.5	14
122	Sequential inflammatory processes define human progression from M. tuberculosis infection to tuberculosis disease. PLoS Pathogens, 2017, 13, e1006687.	4.7	193
123	Mixed Th1 and Th2 Mycobacterium tuberculosis-specific CD4 T cell responses in patients with active pulmonary tuberculosis from Tanzania. PLoS Neglected Tropical Diseases, 2017, 11, e0005817.	3.0	29
124	Impact of Xpert MTB/RIF rollout on management of tuberculosis in a South African community. South African Medical Journal, 2017, 107, 1078.	0.6	15
125	Using biomarkers to predict TB treatment duration (Predict TB): a prospective, randomized, noninferiority, treatment shortening clinical trial. Gates Open Research, 2017, 1, 9.	1.1	22
126	A novel blood test for tuberculosis prevention and treatment. South African Medical Journal, 2016, 107, 4.	0.6	7

#	Article	IF	Citations
127	Correlates of tuberculosis risk: predictive biomarkers for progression to active tuberculosis. European Respiratory Journal, 2016, 48, 1751-1763.	6.7	165
128	BCG and New Preventive Tuberculosis Vaccines: Implications for Healthcare Workers. Clinical Infectious Diseases, 2016, 62, S262-S267.	5.8	13
129	P098 HLA haplotype diversity in Cape Town, South Africa. Human Immunology, 2016, 77, 110.	2.4	0
130	Human newborn bacille Calmetteâ€“GuÃ©rin vaccination and risk of tuberculosis disease: a case-control study. BMC Medicine, 2016, 14, 76.	5.5	55
131	Bacillus Calmetteâ€“GuÃ©rin (BCG) Revaccination of Adults with Latent Mycobacterium tuberculosis Infection Induces Long-Lived BCG-Reactive NK Cell Responses. Journal of Immunology, 2016, 197, 1100-1110.	0.8	121
132	T-cell activation is an immune correlate of risk in BCG vaccinated infants. Nature Communications, 2016, 7, 11290.	12.8	236
133	Teaching advanced flow cytometry in Africa: 10 years of lessons learned. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2016, 89, 971-974.	1.5	2
134	Predicting tuberculosis risk â€“ Authorsâ€™ reply. Lancet, The, 2016, 388, 2233-2234.	13.7	12
135	Vaccination Against Tuberculosis With Whole-Cell Mycobacterial Vaccines. Journal of Infectious Diseases, 2016, 214, 659-664.	4.0	45
136	A Glucuronoxylomannan-Associated Immune Signature, Characterized by Monocyte Deactivation and an Increased Interleukin 10 Level, Is a Predictor of Death in Cryptococcal Meningitis. Journal of Infectious Diseases, 2016, 213, 1725-1734.	4.0	37
137	A blood RNA signature for tuberculosis disease risk: a prospective cohort study. Lancet, The, 2016, 387, 2312-2322.	13.7	678
138	Flow Cytometry To Assess Cerebrospinal Fluid Fungal Burden in Cryptococcal Meningitis. Journal of Clinical Microbiology, 2016, 54, 802-804.	3.9	7
139	Individual-level factors associated with variation in mycobacterial-specific immune response: Gender and previous BCG vaccination status. Tuberculosis, 2016, 96, 37-43.	1.9	6
140	Real-Time Investigation of Tuberculosis Transmission: Developing the Respiratory Aerosol Sampling Chamber (RASC). PLoS ONE, 2016, 11, e0146658.	2.5	40
141	A Quantitative Analysis of Complexity of Human Pathogen-Specific CD4 T Cell Responses in Healthy M. tuberculosis Infected South Africans. PLoS Pathogens, 2016, 12, e1005760.	4.7	128
142	A novel blood test for tuberculosis prevention and treatment. South African Medical Journal, 2016, 107, 4.	0.6	7
143	A Review and Proposed Approach to the Neutrophilic Dermatoses of Childhood. Pediatric Dermatology, 2015, 32, 437-446.	0.9	12
144	Relationship between female genital tract infections, mucosal interleukinâ€17 production and local T helper type 17 cells. Immunology, 2015, 146, 557-567.	4.4	45

#	Article	IF	Citations
145	The Role of Clinical Symptoms in the Diagnosis of Intrathoracic Tuberculosis in Young Children. Pediatric Infectious Disease Journal, 2015, 34, 1157-1162.	2.0	23
146	Risk of Disease After Isoniazid Preventive Therapy for Mycobacterium tuberculosis Exposure in Young HIV-uninfected Children. Pediatric Infectious Disease Journal, 2015, 34, 1218-1222.	2.0	9
147	The impact of HIV exposure and maternal Mycobacterium tuberculosis infection on infant immune responses to bacille Calmette-GuÃ©rin vaccination. Aids, 2015, 29, 155-165.	2.2	47
148	T cells and adaptive immunity to Mycobacterium tuberculosis in humans. Immunological Reviews, 2015, 264, 74-87.	6.0	305
149	The tuberculosis vaccine H4:IC31 is safe and induces a persistent polyfunctional CD4 T cell response in South African adults: A randomized controlled trial. Vaccine, 2015, 33, 3592-3599.	3.8	71
150	Mycobacterium tuberculosis-specific CD4 T cells are the principal source of IFN-Î³ in QuantiFERON assays in healthy persons. Tuberculosis, 2015, 95, 350-351.	1.9	12
151	COMPASS identifies T-cell subsets correlated with clinical outcomes. Nature Biotechnology, 2015, 33, 610-616.	17.5	232
152	The Dynamics of QuantiFERON-TB Gold In-Tube Conversion and Reversion in a Cohort of South African Adolescents. American Journal of Respiratory and Critical Care Medicine, 2015, 191, 584-591.	5.6	108
153	A side-by-side comparison of T cell reactivity to fifty-nine Mycobacterium tuberculosis antigens in diverse populations from five continents. Tuberculosis, 2015, 95, 713-721.	1.9	35
154	First-in-human trial of the post-exposure tuberculosis vaccine H56:IC31 in Mycobacterium tuberculosis infected and non-infected healthy adults. Vaccine, 2015, 33, 4130-4140.	3.8	183
155	Development and validation of a broad scheme for prediction of HLA class II restricted T cell epitopes. Journal of Immunological Methods, 2015, 422, 28-34.	1.4	171
156	A Population Response Analysis Approach To Assign Class II HLA-Epitope Restrictions. Journal of Immunology, 2015, 194, 6164-6176.	0.8	51
157	Combined Use of Mycobacterium tuberculosisâ€“Specific CD4 and CD8 T-Cell Responses Is a Powerful Diagnostic Tool of Active Tuberculosis. Clinical Infectious Diseases, 2015, 60, 432-437.	5.8	75
158	A double-blind, randomised, placebo-controlled, dose-finding trial of the novel tuberculosis vaccine AERAS-402, an adenovirus-vectored fusion protein, in healthy, BCG-vaccinated infants. Vaccine, 2015, 33, 2944-2954.	3.8	47
159	T Cell Responses against Mycobacterial Lipids and Proteins Are Poorly Correlated in South African Adolescents. Journal of Immunology, 2015, 195, 4595-4603.	0.8	27
160	The TB-specific CD4+ T cell immune repertoire in both cynomolgus and rhesus macaques largely overlap with humans. Tuberculosis, 2015, 95, 722-735.	1.9	39
161	A randomized clinical trial in adults and newborns in South Africa to compare the safety and immunogenicity of bacille Calmette-GuÃ©rin (BCG) vaccine administration via a disposable-syringe jet injector to conventional technique with needle and syringe. Vaccine, 2015, 33, 4719-4726.	3.8	17
162	Safety and immunogenicity of candidate vaccine M72/AS01E in adolescents in a TB endemic setting. Vaccine, 2015, 33, 4025-4034.	3.8	110

#	Article	IF	Citations
163	Differential leukocyte counting and immunophenotyping in cryopreserved ex vivo whole blood. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2015, 87, 157-165.	1.5	23
164	Qualification of a whole blood intracellular cytokine staining assay to measure mycobacteria-specific CD4 and CD8 T cell immunity by flow cytometry. Journal of Immunological Methods, 2015, 417, 22-33.	1.4	68
165	Evaluation of XpertÂ® MTB/RIF Assay in Induced Sputum and Gastric Lavage Samples from Young Children with Suspected Tuberculosis from the MVA85A TB Vaccine Trial. PLoS ONE, 2015, 10, e0141623.	2.5	19
166	The Candidate TB Vaccine, MVA85A, Induces Highly Durable Th1 Responses. PLoS ONE, 2014, 9, e87340.	2.5	79
167	Distinct T-Cell Responses When BCG Vaccination Is Delayed From Birth to 6 Weeks of Age in Ugandan Infants. Journal of Infectious Diseases, 2014, 209, 887-897.	4.0	29
168	Process of Assay Selection and Optimization for the Study of Case and Control Samples from a Phase IIb Efficacy Trial of a Candidate Tuberculosis Vaccine, MVA85A. Vaccine Journal, 2014, 21, 1005-1011.	3.1	15
169	Tuberculosis Vaccines and Prevention of Infection. Microbiology and Molecular Biology Reviews, 2014, 78, 650-671.	6.6	133
170	Serum indoleamine 2,3-dioxygenase activity is associated with reduced immunogenicity following vaccination with MVA85A. BMC Infectious Diseases, 2014, 14, 660.	2.9	20
171	Time to Symptom Resolution in Young Children Treated for Pulmonary Tuberculosis. Pediatric Infectious Disease Journal, 2014, 33, 1226-1230.	2.0	7
172	Differential gene expression of activating FcÎ³ receptor classifies active tuberculosis regardless of human immunodeficiency virus status or ethnicity. Clinical Microbiology and Infection, 2014, 20, O230-O238.	6.0	65
173	Inflammatory and myeloid-associated gene expression before and one day after infant vaccination with MVA85A correlates with induction of a T cell response. BMC Infectious Diseases, 2014, 14, 314.	2.9	24
174	The novel tuberculosis vaccine, AERAS-402, is safe in healthy infants previously vaccinated with BCG, and induces dose-dependent CD4 and CD8T cell responses. Vaccine, 2014, 32, 5908-5917.	3.8	41
175	Maturation of Innate Responses to Mycobacteria over the First Nine Months of Life. Journal of Immunology, 2014, 192, 4833-4843.	0.8	33
176	Effect of Isoniazid Therapy for Latent TB Infection on QuantiFERON-TB Gold In-Tube Responses in Adults With Positive Tuberculin Skin Test Results in a High TB Incidence Area. Chest, 2014, 145, 612-617.	0.8	37
177	St John's Wort (Hypericum perforatum L.) Photomedicine: Hypericin-Photodynamic Therapy Induces Metastatic Melanoma Cell Death. PLoS ONE, 2014, 9, e103762.	2.5	83
178	Safety and Immunogenicity of H1/IC31Â®, an Adjuvanted TB Subunit Vaccine, in HIV-Infected Adults with CD4+ Lymphocyte Counts Greater than 350 cells/mm3: A Phase II, Multi-Centre, Double-Blind, Randomized, Placebo-Controlled Trial. PLoS ONE, 2014, 9, e114602.	2.5	52
179	A strategy to determine HLA class II restriction broadly covering the DR, DP, and DQ allelic variants most commonly expressed in the general population. Immunogenetics, 2013, 65, 357-370.	2.4	77
180	Longitudinal Changes in CD4+ T-Cell Memory Responses Induced by BCG Vaccination of Newborns. Journal of Infectious Diseases, 2013, 207, 1084-1094.	4.0	120

#	Article	IF	Citations
181	Heterologous vaccination against human tuberculosis modulates antigenâ€specific <scp>CD</scp>4⁺<scp>T</scp>â€cell function. European Journal of Immunology, 2013, 43, 2409-2420.	2.9	26
182	Lessons learnt from the first efficacy trial of a new infant tuberculosis vaccine since BCG. Tuberculosis, 2013, 93, 143-149.	1.9	35
183	Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial. Lancet, The, 2013, 381, 1021-1028.	13.7	903
184	Relationship between chemokine receptor expression, chemokine levels and HIV â€1 replication in the lungs of persons exposed to M ycobacterium tuberculosis. European Journal of Immunology, 2013, 43, 540-549.	2.9	19
185	Varicella Zosterâ€"Specific CD4+Foxp3+ T Cells Accumulate after Cutaneous Antigen Challenge in Humans. Journal of Immunology, 2013, 190, 977-986.	0.8	50
186	Human MAIT and CD8Î±Î± cells develop from a pool of type-17 precommitted CD8+ T cells. Blood, 2012, 119, 422-433.	1.4	239
187	A Phase IIa Trial of the New Tuberculosis Vaccine, MVA85A, in HIV- and/or Mycobacterium tuberculosisâ€"infected Adults. American Journal of Respiratory and Critical Care Medicine, 2012, 185, 769-778.	5.6	78
188	SATVI - after 10 years closing in on a new and better vaccine to prevent tuberculosis. South African Medical Journal, 2012, 102, 438.	0.6	3
189	Optimization of a whole blood intracellular cytokine assay for measuring innate cell responses to mycobacteria. Journal of Immunological Methods, 2012, 376, 79-88.	1.4	16
190	HIVâ€1 infection alters CD4⁺ memory Tâ€cell phenotype at the site of disease in extrapulmonary tuberculosis. European Journal of Immunology, 2012, 42, 147-157.	2.9	38
191	Identification of Antigens Specific to Non-Tuberculous Mycobacteria: The Mce Family of Proteins as a Target of T Cell Immune Responses. PLoS ONE, 2011, 6, e26434.	2.5	20
192	Immunological biomarkers of tuberculosis. Nature Reviews Immunology, 2011, 11, 343-354.	22.7	455
193	Predominance of interleukin-22 over interleukin-17 at the site of disease in human tuberculosis. Tuberculosis, 2011, 91, 587-593.	1.9	71
194	Dose-Finding Study of the Novel Tuberculosis Vaccine, MVA85A, in Healthy BCG-Vaccinated Infants. Journal of Infectious Diseases, 2011, 203, 1832-1843.	4.0	75
195	Modified vaccinia Ankaraâ€expressing Ag85A, a novel tuberculosis vaccine, is safe in adolescents and children, and induces polyfunctional CD4⁺ T cells. European Journal of Immunology, 2010, 40, 279-290.	2.9	171
196	Novel application of Ki67 to quantify antigen-specific in vitro lymphoproliferation. Journal of Immunological Methods, 2010, 362, 43-50.	1.4	140
197	Single nucleotide polymorphisms in toll-like receptor 6 are associated with altered lipopeptide- and mycobacteria-induced interleukin-6 secretion. Genes and Immunity, 2010, 11, 561-572.	4.1	58
198	CD4 and CD8 T-Cell Responses to Mycobacterial Antigens in African Children. American Journal of Respiratory and Critical Care Medicine, 2010, 182, 120-129.	5.6	50

#	Article	IF	Citations
199	Specific T Cell Frequency and Cytokine Expression Profile Do Not Correlate with Protection against Tuberculosis after Bacillus Calmette-GuÃ©rin Vaccination of Newborns. American Journal of Respiratory and Critical Care Medicine, 2010, 182, 1073-1079.	5.6	386
200	Higher human CD4 T cell response to novel Mycobacterium tuberculosis latency associated antigens Rv2660 and Rv2659 in latent infection compared with tuberculosis disease. Vaccine, 2010, 29, 51-57.	3.8	64
201	HIV-1 Infection Impairs the Bronchoalveolar T-Cell Response to Mycobacteria. American Journal of Respiratory and Critical Care Medicine, 2009, 180, 1262-1270.	5.6	138
202	Significantly skewed memory CD8+ T cell subsets in HIV-1 infected infants during the first year of life. Clinical Immunology, 2009, 130, 280-289.	3.2	28
203	Delaying BCG vaccination from birth to 10 weeks of age may result in an enhanced memory CD4 T cell response. Vaccine, 2009, 27, 5488-5495.	3.8	117
204	HIVâ€1 Infection in Infants Severely Impairs the Immune Response Induced by Bacille Calmetteâ€GuÃ©rin Vaccine. Journal of Infectious Diseases, 2009, 199, 982-990.	4.0	88
205	Human immunodeficiency virus (HIV)-specific T helper responses fail to predict CD4+ T cell decline following short-course treatment at primary HIV-1 infection. Clinical and Experimental Immunology, 2008, 152, 532-537.	2.6	6
206	A comparison of IFNÎ³ detection methods used in tuberculosis vaccine trials. Tuberculosis, 2008, 88, 631-640.	1.9	47
207	Bacillus Calmette-Guèrin Vaccination of Human Newborns Induces T Cells with Complex Cytokine and Phenotypic Profiles. Journal of Immunology, 2008, 180, 3569-3577.	0.8	236
208	TheStaphyloccous aureusEap Protein Activates Expression of Proinflammatory Cytokines. Infection and Immunity, 2008, 76, 2164-2168.	2.2	21
209	Safety and Immunogenicity of a New Tuberculosis Vaccine, MVA85A, in Healthy Adults in South Africa. Journal of Infectious Diseases, 2008, 198, 544-552.	4.0	155
210	Distinct, Specific IL-17- and IL-22-Producing CD4+ T Cell Subsets Contribute to the Human Anti-Mycobacterial Immune Response. Journal of Immunology, 2008, 180, 1962-1970.	0.8	378
211	Dramatically Impaired BCGâ€specific Immune Response in HIV+ Infants. FASEB Journal, 2008, 22, 496-496.	0.5	0
212	Precise Identification of a Human Immunodeficiency Virus Type 1 Antigen Processing Mutant. Journal of Virology, 2007, 81, 2031-2038.	3.4	30
213	Use of Peptide-Major Histocompatibility Complex Tetramer Technology To Study Interactions betweenStaphylococcus aureusProteins and Human Cells. Infection and Immunity, 2007, 75, 5711-5715.	2.2	10
214	Tracking Virus-Specific CD4+ T Cells during and after Acute Hepatitis C Virus Infection. PLoS ONE, 2007, 2, e649.	2.5	65
215	Immunological protection against tuberculosis. South African Medical Journal, 2007, 97, 973-7.	0.6	11
216	Impaired IFN-Î³-secreting capacity in mycobacterial antigen-specific CD4 T cells during chronic HIV-1 infection despite long-term HAART. Aids, 2006, 20, 821-829.	2.2	63

#	Article	IF	Citations
217	Identification of key peptide-specific CD4+T cell responses to human cytomegalovirus: implications for tracking antiviral populations. Clinical and Experimental Immunology, 2006, 146, 203-210.	2.6	10
218	Anti-coreceptor antibodies profoundly affect staining with peptide-MHC class I and class II tetramers. European Journal of Immunology, 2006, 36, 1847-1855.	2.9	22
219	Ultrasensitive Detection and Phenotyping of CD4+ T Cells with Optimized HLA Class II Tetramer Staining. Journal of Immunology, 2005, 175, 6334-6343.	0.8	85
220	Functionally-inactive and immunogenic Tat, Rev and Nef DNA vaccines derived from sub-Saharan subtype C human immunodeficiency virus type 1 consensus sequences. Vaccine, 2005, 23, 1158-1169.	3.8	16
221	HIV-1â€“specific CD4+ T lymphocyte turnover and activation increase upon viral rebound. Journal of Clinical Investigation, 2005, 115, 443-450.	8.2	44
222	HIV-1â€“specific CD4+ T lymphocyte turnover and activation increase upon viral rebound. Journal of Clinical Investigation, 2005, 115, 443-450.	8.2	30
223	Functional analysis of novel SLC11A1 (NRAMP1) promoter variants in susceptibility to HIV-1. Journal of Medical Genetics, 2004, 41, e49-e49.	3.2	16
224	Characterization of the South African HIV Type 1 Subtype C Complete 5â€² Long Terminal Repeat,nef,and Regulatory Genes. AIDS Research and Human Retroviruses, 2002, 18, 149-159.	1.1	14
225	Novel Evolutionary Analyses of Full-Length HIV Type 1 Subtype C Molecular Clones from Cape Town, South Africa. AIDS Research and Human Retroviruses, 2002, 18, 1327-1332.	1.1	14
226	African-based CCR5 single-nucleotide polymorphism associated with HIV-1 disease progression. Aids, 2002, 16, 2229-2231.	2.2	10
227	Characterization and Phylogenetic Analysis of South African HIV-1 Subtype C Accessory Genes. AIDS Research and Human Retroviruses, 2001, 17, 775-781.	1.1	22